FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Sarepta Disregards FDA Request to Stop Shipping Elevidys

Sarepta brushes off an informal request from FDA to voluntarily halt shipment of Elevidys (delandistrogene moxeparvovec), a gene therapy for Duchenne ...

latest-news-card-1
Human Drugs

Roche Reports Mixed Data on COPD Studies

Roche reports mixed data on its investigational chronic obstructive pulmonary disease drug astegolimab in two key late-stage clinical trials.

Animal Drugs

Guide on Biosimilar Formal Meeting Requsts

FDA releases a final guidance entitled Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products.

latest-news-card-1
Medical Devices

SunMed Manual Resuscitators Recalled

SunMed Holdings recalls its Adult Manual Resuscitator devices due to incorrect assembly of the bacterial/viral filter.

latest-news-card-1
Marketing

Sen. Durbin Calls for Crackdown on DTC Telehealth

Senator Dick Durbin (D-IL) calls for a crackdown on pharmaceutical companies growing use of direct-to-consumer telehealth platforms due to concerns ab...

latest-news-card-1
Human Drugs

ICH Guide on Including Pregnant Women in Trials

FDA posts an International Conference on Harmonization draft guidance entitled E21 Inclusion of Pregnant and Breastfeeding Women in Clinical Trials.

latest-news-card-1
Human Drugs

FDA Rejects Genentechs Bid to Expand Columvi Use

FDA rejects Genentechs bid to broaden the use of its lymphoma drug Columvi.

latest-news-card-1
Human Drugs

Panel Votes Down Rexulti for PTSD

FDAs Psychopharmacologic Drugs Advisory Committee votes against approving an Otsuka Pharma NDA for Rexulti (brexpiprazole) when used in combination wi...

latest-news-card-1
Biologics

FDA Mulls Pulling Sareptas Gene Therapy

An HHS official says FDA is taking a hard look at pulling from the market Sarepta Therapeutics gene therapy Elevidys (delandistrogene moxeparvov...

latest-news-card-1

CDER Losing Staff In Droves: Report

An online post details a significant number of resignations from CDER in the first six months of this year.